Gorlin Syndrome — designated Gorlin-Goltz syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome (NBCCS), an autosomal dominant hereditary multisystem syndrome caused by germline pathogenic variants in the PTCH1 tumor suppressor gene (chromosome 9q22.32, OMIM #109400) encoding the Patched 1 receptor, or less commonly PTCH2 (chromosome 1p32.3), with a prevalence estimated at 1 in 31,000–60,000 individuals and near-complete penetrance for at least one major clinical criterion, arising from dysregulation of the hedgehog (HH) signaling pathway — one of the most evolutionarily conserved developmental signaling cascades — where the PTCH1 transmembrane protein acts as a constitutive inhibitor of Smoothened (SMO), the G-protein-coupled receptor that activates the downstream GLI transcription factors GLI1 and GLI2 when hedgehog ligands (Sonic, Desert, or Indian hedgehog) are absent, maintaining PTCH1's inhibitory interaction with SMO and preventing pathway activation in unstimulated cells; pathogenic PTCH1 loss-of-function mutations — including nonsense, frameshift, splice site, and large deletion variants distributed throughout the gene with no clear genotype-phenotype hotspot, plus PTCH2 missense mutations in a smaller fraction of patients — remove PTCH1's constitutive SMO inhibition, producing aberrant GLI1/GLI2 nuclear signaling that drives proliferative, anti-apoptotic, and stem cell transcriptional programs and underlies the syndrome's characteristic neoplastic manifestations: multiple basal cell carcinomas (BCCs) — occurring in 90% of Caucasian patients (lower penetrance in darker-pigmented individuals) from adolescence and young adulthood, with patients frequently developing hundreds to thousands of BCCs over their lifetime, spanning superficial, nodular, and morpheaform subtypes, occurring predominantly at sun-exposed head, neck, and trunk sites but distinctively also at radiation-protected sites including the axillae, inguinal folds, and genitalia where sporadic BCCs virtually never arise, with each BCC carrying a somatic second-hit PTCH1 mutation plus epigenetic silencing or UV-signature mutations consistent with somatic loss of heterozygosity at 9q22 confirming the classical two-hit tumor suppressor mechanism; medulloblastoma — predominantly the desmoplastic/nodular histological variant occurring in young children (peak incidence 2–3 years), arising in 5% of Gorlin patients and representing approximately 5–10% of all childhood medulloblastomas, whose importance lies disproportionately in the catastrophic radiation-induced BCC formation that craniospinal irradiation — standard-of-care for many medulloblastoma subtypes — causes in Gorlin patients, where the radiation field triggers thousands of BCCs within weeks to months of treatment in a patient whose germline PTCH1 mutation makes every radiation-exposed basal cell susceptible to neoplastic transformation with a single additional hit, making radiation-free medulloblastoma protocols (high-dose chemotherapy with stem cell rescue in Gorlin patients) a critical treatment modification that can only be implemented if Gorlin syndrome is diagnosed before radiotherapy begins; keratocystic odontogenic tumors (KCOTs) of the jaw — formerly called odontogenic keratocysts — present in 75–90% of Gorlin patients, developing throughout the mandible and maxilla from early childhood to middle age, often appearing before the first BCCs and serving as an early diagnostic clue, demonstrating high recurrence rates after enucleation (up to 60%) due to satellite cell islands, and rarely undergoing ameloblastoma-like or squamous transformation; calcified falx cerebri — present in 65–79% of adult patients on skull radiograph or CT, often the first radiological finding suggesting Gorlin syndrome in an adult presenting with BCCs; bifid ribs, vertebral anomalies, and other skeletal developmental variants; cardiac fibromas — benign but potentially arrhythmogenic cardiac tumors present in approximately 2% of patients; ovarian fibromas — present in 17–24% of female patients, often bilateral, occasionally calcified (particularly in Gorlin patients versus sporadic ovarian fibromas), detectable on pelvic ultrasound and important for surgical planning; meningiomas with higher frequency than general population; and distinct facial dysmorphism including macrocephaly, frontal bossing, coarse facial features, and hypertelorism — making Gorlin syndrome the archetypal neurocutaneous tumor predisposition syndrome where hedgehog pathway constitutive activation drives synchronous tumor formation across skin, brain, jaw, heart, and ovaries, with the radiation sensitivity phenotype creating treatment modification imperatives that require prospective Gorlin diagnosis rather than retrospective recognition.
Gorlin syndrome technology platforms — encompassing the clinical genetics and dermatological genetics platforms where initial Gorlin syndrome diagnosis is established through PTCH1/PTCH2 germline sequencing in probands presenting with multiple BCCs at young age, jaw KCOTs, or childhood desmoplastic medulloblastoma, and where cascade testing of at-risk family members identifies carriers who can initiate primary and secondary prevention programs before BCC accumulation, the dermatology platforms providing the intensive BCC surveillance and treatment that constitutes the highest-frequency clinical obligation in Gorlin management across the lifetime of affected patients, the oral and maxillofacial surgery and dental radiology platforms providing the panoramic radiograph surveillance and KCOT management that requires lifelong jaw surveillance starting in childhood, the neuro-oncology platforms managing desmoplastic medulloblastoma in young children with Gorlin syndrome through radiation-avoiding chemotherapy protocols, the neuroradiology platforms providing brain MRI surveillance for medulloblastoma in young children and meningioma screening in adults, the cardiac imaging platforms performing echocardiography for cardiac fibroma detection and arrhythmia monitoring, the gynecological and pelvic ultrasound platforms detecting ovarian fibromas, the radiation oncology platforms where awareness of Gorlin syndrome prevents catastrophic radiation-induced BCC formation by prompting radiation-free treatment planning wherever oncologically feasible, the dermatological oncology platforms managing advanced and metastatic BCCs with hedgehog pathway inhibitors (vismodegib, sonidegib), the photodynamic therapy and field-treatment platforms providing non-surgical approaches to field cancerization in patients with diffuse superficial BCCs, and the multidisciplinary Gorlin syndrome specialty clinic platforms coordinating the lifelong surveillance calendar that each Gorlin patient navigates — must maintain the availability and performance standards required by the surveillance-intensive, radiation-avoidance-critical, BCC-burden-management-intensive, and multi-organ monitoring demands of this complex hereditary BCC and tumor predisposition syndrome. This guide explains why Gorlin syndrome tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the dermatological, dental, neurological, cardiac, and gynecological surveillance obligations that define modern Gorlin syndrome management.
Why Gorlin Syndrome Tech Platforms Require Specialized Monitoring Attention
Gorlin syndrome management is defined by several uniquely complex surveillance and treatment challenges: the radiation-avoidance imperative as an existential treatment modification — in any Gorlin patient requiring treatment for a co-occurring malignancy (medulloblastoma, meningioma, or any other radiation-indicated cancer), the knowledge that germline PTCH1 mutation renders all radiation-exposed basal cells susceptible to catastrophic BCC induction must be communicated to radiation oncology planning teams before any treatment begins, and healthcare platform unavailability that delays the Gorlin diagnosis, delays access to the germline testing result, or fails to surface the Gorlin annotation in a treatment planning system can result in craniospinal irradiation of a Gorlin patient — a clinical catastrophe that is completely preventable given prospective diagnosis; the BCC surveillance and treatment volume challenge — Gorlin patients may require dozens of BCC treatments per year, generating a high-frequency dermatological surveillance load that requires reliable platform availability throughout the clinical lifetime of each affected patient; the early childhood jaw and brain surveillance mandate — KCOT and medulloblastoma surveillance beginning in early childhood creates a pediatric surveillance obligation whose platform reliability determines whether medulloblastoma is caught before it becomes symptomatic and requiring radiation or before surgical morbidity increases; and the hedgehog inhibitor therapeutic monitoring requirement — vismodegib and sonidegib produce treatment-response assessment needs (imaging, toxicity monitoring, interruption scheduling) that require reliable platform availability.
Dermatology platforms for BCC surveillance and treatment are the highest-frequency clinical obligation in Gorlin management. Gorlin patients require full-body skin examination every 3–6 months for BCC detection, with photographic mapping and dermoscopy of high-risk lesions, and treatment of identified BCCs by excision, curettage and electrodesiccation, imiquimod, photodynamic therapy, or hedgehog inhibitor therapy — a volume and frequency of dermatological encounters whose platform availability directly determines whether BCCs are caught at early, locally treatable stages. Monitor dermatology platforms at 1-minute intervals during clinical hours.
Panoramic jaw radiograph and KCOT surveillance platforms detect jaw keratocysts before painful expansion and pathological fracture. Gorlin patients require panoramic radiograph surveillance starting in childhood for KCOT development — often the first diagnostic finding in Gorlin syndrome — with KCOTs requiring enucleation, marsupialization, or resection and having high local recurrence rates demanding serial post-treatment surveillance. Monitor dental radiology platforms at 1-minute intervals during radiology hours.
Pediatric brain MRI platforms detect medulloblastoma at surgically treatable stages in at-risk young children. Children under 7 with germline Gorlin syndrome diagnosis or strong clinical suspicion require annual brain MRI — the detection window for medulloblastoma in the 5% at risk — where early detection enables surgical resection followed by radiation-free chemotherapy rather than emergency surgery with potential subsequent irradiation. Monitor pediatric neuroradiology platforms at 1-minute intervals during radiology hours.
Radiation oncology consultation and treatment planning platforms must surface Gorlin syndrome diagnosis before any ionizing radiation treatment decision. Any platform responsible for treatment planning, diagnosis flagging, or clinical decision support in Gorlin patients must reliably surface the Gorlin/PTCH1 status before radiation therapy is initiated for any indication. Monitor radiation oncology platforms at 1-minute intervals during clinical hours.
What to Monitor on a Gorlin Syndrome Care Tech Platform
PTCH1/PTCH2 Molecular Genetics and Cascade Testing
Monitor PTCH1/PTCH2 germline sequencing records (full coding sequence sequencing by next-generation sequencing or Sanger; large deletion/duplication analysis by MLPA or chromosomal microarray — large deletions accounting for 10–20% of PTCH1 mutations; PTCH2 sequencing for PTCH1-negative clinical Gorlin syndrome; variant pathogenicity classification by ACMG criteria; mosaic PTCH1 mutation detection in atypical presentations), functional studies records (GLI luciferase reporter assays, sonic hedgehog binding assays, and PTCH1 complementation studies for VUS resolution), cascade family testing records (at-risk first-degree relatives offered germline testing from early childhood — testing before age 5 enables pre-BCC primary prevention counseling and radiation-avoidance genetic alert generation; affected parent testing to confirm PTCH1 status for treatment planning), and radiation-avoidance alert records (Gorlin syndrome/PTCH1 status flagged in electronic health record for every affected patient — alert visible to radiation oncology planning teams before any radiation treatment order is entered; institutional alert protocols; radiation sensitivity counseling documentation) — at a 1-minute interval during laboratory hours.
Dermatology — BCC Surveillance, Treatment, and Field Management
Monitor BCC surveillance records (full-body skin examination every 3–6 months; total body photography for lesion mapping and interval change detection; dermoscopy for BCC characterization — arborizing vessels, blue-gray ovoid nests, leaf-like areas; lesion number, size, location, and clinical subtype documentation; photographic comparison for growth rate assessment; treatment decision records — excision versus destructive versus topical versus systemic), BCC treatment records (excision pathology records — margin assessment, BCC subtype histology, perineural invasion; curettage and electrodesiccation records; Mohs micrographic surgery for face, ears, and hands; imiquimod 5% cream application records for superficial BCCs — field treatment; photodynamic therapy records — 5-ALA or MAL application, illumination parameters, field treatment for superficial BCCs; dermabrasion records for field treatment; laser therapy records), hedgehog inhibitor records (vismodegib 150 mg daily — hedgehog pathway inhibitor FDA-approved for locally advanced and metastatic BCC; sonidegib 200 mg daily — alternative HHI; BCC response documentation — tumor reduction, new lesion inhibition; treatment interruption scheduling for toxicity management — muscle cramps, alopecia, dysgeusia, amenorrhea, teratogenicity counseling; cycle therapy protocols for Gorlin patients — 12 weeks on, 8 weeks off; KCOT response to vismodegib; medulloblastoma response records in inoperable cases), and metastatic BCC records (cemiplimab PD-1 inhibitor for hedgehog inhibitor-resistant locally advanced or metastatic BCC; combination checkpoint inhibitor and HHI protocols; staging CT for locoregional and distant metastatic BCC assessment) — at a 1-minute interval during clinical hours. Alert immediately — BCC surveillance platform failures during the 3-to-6-monthly dermatological examination of a Gorlin patient with high tumor burden delay the photographic comparison needed to identify rapidly growing BCCs approaching locally advanced stage and the new lesion count needed to assess hedgehog inhibitor response or initiation indication.
Oral and Maxillofacial — Jaw KCOT Surveillance and Management
Monitor panoramic radiograph records (annual or biennial panoramic jaw radiograph from age 8–10 in Gorlin patients; KCOT characterization — unilocular versus multilocular, cortical expansion, tooth displacement, cortical perforation; KCOT anatomical distribution — mandibular posterior > anterior, maxillary posterior > anterior; new KCOT development documentation; post-treatment surveillance for KCOT recurrence — panoramic radiograph every 6–12 months for 5 years after enucleation given high recurrence rate), KCOT surgical records (enucleation with peripheral ostectomy; marsupialization for large cysts with cortical thinning — two-stage decompression then enucleation; resection for multiply recurrent, large, or suspicious KCOTs; carnoy solution application; cryotherapy; pathological specimen documentation — keratocystic odontogenic tumor confirmed histology; parakeratinized epithelium with palisaded basal cell layer), dental rehabilitation records (dental implants after KCOT resection; orthodontic management for displaced teeth; prosthetic rehabilitation), MRI jaw records (MRI for soft tissue assessment of KCOT with cortical perforation, nerve involvement, or suspected malignant transformation), and CT jaw records (cone beam CT or MDCT for surgical planning, cortical breach assessment, and recurrence characterization) — at a 1-minute interval during radiology hours.
Pediatric Neuro-oncology — Medulloblastoma Surveillance and Management
Monitor pediatric brain MRI records (annual brain MRI with gadolinium in Gorlin children aged 0–7 years for medulloblastoma surveillance; cerebellar vermis and fourth ventricular region — the desmoplastic/nodular medulloblastoma site of origin in Gorlin syndrome; posterior fossa mass characterization — T1 hypointense, T2 heterogeneous, gadolinium-enhancing; leptomeningeal dissemination assessment on spinal MRI; fourth ventricular obstruction and hydrocephalus), medulloblastoma staging and treatment records (Chang staging; surgical resection records — gross total resection intent; intraoperative frozen section for desmoplastic/nodular histology confirmation triggering Gorlin-specific treatment protocol; PTCH1 molecular subgrouping confirmatory testing — sonic hedgehog molecular subgroup; radiation-free chemotherapy protocol records — carboplatin, vincristine, cyclophosphamide regimens for average-risk Gorlin medulloblastoma; high-dose chemotherapy with autologous stem cell rescue for high-risk Gorlin medulloblastoma; long-term neurological outcome documentation), and radiation avoidance documentation records (explicit documentation that craniospinal irradiation was avoided in Gorlin patient; alternative treatment rationale; clinical trial enrollment if available) — at a 1-minute interval during radiology and clinical hours.
Cardiac Surveillance — Cardiac Fibroma Detection
Monitor echocardiography records (echocardiography in Gorlin children for cardiac fibroma detection — myocardial mass characterization, location, size, and effect on cardiac function; interventricular septal location most common; left ventricular mass; arrhythmia risk assessment; outflow tract obstruction evaluation), cardiac MRI records (cardiac MRI for detailed fibroma characterization — T2 hypointense fibrous tissue signal; gadolinium late enhancement pattern; multiplanar tumor localization for surgical planning), arrhythmia monitoring records (12-lead ECG; ambulatory Holter monitoring for ventricular arrhythmia in patients with cardiac fibromas; arrhythmia management — antiarrhythmic therapy or implantable cardioverter-defibrillator in high-risk patients), and cardiac surgical records (cardiac fibroma resection — partial resection for large fibromas causing hemodynamic compromise or refractory arrhythmia; outcomes documentation) — at a 1-minute interval during clinical hours.
Gynecological Surveillance — Ovarian Fibroma Detection
Monitor pelvic ultrasound records (annual pelvic ultrasound in female Gorlin patients from puberty; ovarian fibroma detection — bilateral assessment, fibroma morphology, calcification pattern characteristic of Gorlin-associated fibromas; ovarian volume and morphology; fibroma size and growth rate), MRI pelvis records (MRI for surgical planning of ovarian fibromas — fibroma characterization, bilateral ovarian preservation planning, adhesion assessment), surgical records (ovarian-sparing fibroma resection for Gorlin patients given bilateral disease risk and fertility implications; oophorectomy records when fibroma is the dominant ovarian tissue; histological confirmation of ovarian fibroma versus thecoma or other sex cord-stromal tumor), and gynecological oncology records (rare malignant transformation surveillance — ovarian fibrosarcoma in Gorlin patients; CA-125 records in patients with suspicious ovarian masses) — at a 1-minute interval during clinical hours.
Neurological and Skeletal Surveillance
Monitor skull radiograph or head CT records (calcified falx cerebri documentation — lamellar calcification of falx on lateral skull radiograph or CT, present in 65–79% by age 20; tentorium cerebelli calcification; clinoid process calcification; bridging of sella turcica), spinal radiograph records (bifid ribs identification; cervical and thoracic vertebral anomalies — hemivertebrae, vertebral fusion; scoliosis assessment), meningioma surveillance records (annual or biennial brain MRI in adult Gorlin patients for meningioma screening given increased meningioma prevalence; meningioma surgical and radiosurgical treatment records — radiation avoidance maintained; long-term cognitive outcome in radiation-free treatments), and developmental and neuropsychological records (macrocephaly monitoring — head circumference serial measurement in children; hydrocephalus detection; neuropsychological assessment for learning disability co-occurring in some Gorlin patients) — at a 1-minute interval during radiology hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Gorlin syndrome management coordinates across clinical genetics (PTCH1/PTCH2 germline testing and cascade family testing), dermatology (BCC surveillance and treatment throughout adult life), dermatological oncology (vismodegib/sonidegib therapy and advanced BCC management), oral and maxillofacial surgery (KCOT surveillance and treatment), dentistry and dental radiology (panoramic radiograph surveillance), pediatric neuro-oncology (medulloblastoma management), neuroradiology (brain MRI for medulloblastoma and meningioma), radiation oncology (where Gorlin status must trigger radiation-avoidance alerting), cardiology (cardiac fibroma echocardiography), gynecology (ovarian fibroma surveillance), ophthalmology (periorbital BCC management), and genetic counseling (family cascade testing and reproductive planning) — authentication failures block access across all these disciplines simultaneously and create particular risk when the authenticated radiation oncology treatment planning workflow is the platform through which Gorlin syndrome status must surface.
SSL Certificates
Monitor SSL certificate expiry across all molecular genetics platforms, dermatology clinical systems, dental radiology portals, pediatric neuro-oncology platforms, cardiac imaging systems, gynecological surveillance platforms, and radiation oncology treatment planning systems. Certificate errors in radiation oncology systems are especially consequential given the Gorlin-specific radiation-avoidance requirement: a treatment planning system certificate error that prevents Gorlin annotation from displaying before a radiation therapy order is entered carries clinical safety implications beyond typical system downtime.
HIPAA and Hereditary Tumor Predisposition Patient Privacy Considerations
Gorlin syndrome technology platforms handle highly sensitive PHI for patients carrying germline PTCH1/PTCH2 pathogenic variants whose genetic status has direct implications for insurance eligibility, educational accommodation, and family members who may or may not wish to know their own carrier status. Records include PTCH1/PTCH2 germline sequencing confirming hereditary BCC predisposition, longitudinal dermatology records documenting lifetime BCC burden (number, location, and treatment history of potentially hundreds of tumors), medulloblastoma diagnosis and chemotherapy records from early childhood, dental and maxillofacial records documenting lifelong KCOT burden, cardiac fibroma echocardiography and surgical records, ovarian fibroma surgical and fertility records, and the critical radiation-avoidance documentation that serves both clinical safety and legal accountability functions.
Germline PTCH1 data triggers GINA (Genetic Information Nondiscrimination Act) protections for employment and health insurance genetic discrimination. The BCC burden documentation — potentially listing hundreds of treated BCCs in a young adult — requires careful minimum-necessary-disclosure practices under the HIPAA Privacy Rule, as the cumulative BCC count reveals the severity of the underlying hereditary syndrome in ways that standard cancer disclosure rules may not fully anticipate.
Alerting Strategy for Gorlin Syndrome Tech Platforms
Immediate 24/7 alerting for authentication: Gorlin care coordination is continuous across BCC surveillance, dental surveillance, and pediatric medulloblastoma monitoring.
Immediate clinical-hours alerting for dermatology platforms: BCC surveillance every 3–6 months and hedgehog inhibitor monitoring require reliable platform availability throughout the clinical day.
Immediate radiology-hours alerting for jaw panoramic radiograph, pediatric brain MRI, and cardiac imaging platforms: KCOT surveillance, medulloblastoma detection, and cardiac fibroma monitoring depend on reliable imaging platform availability.
Immediate clinical-hours alerting for radiation oncology platforms: The radiation-avoidance imperative requires Gorlin syndrome status to surface in radiation oncology treatment planning platforms without failure.
Sustained-failure alert (10–15 minutes): Ovarian fibroma surveillance, meningioma monitoring, skeletal surveillance, and genetic counseling coordination platforms.
30-day advance warning: SSL certificates across all domains — with immediate escalation protocols for radiation oncology treatment planning system certificate failures.
Vigilmon's multi-region monitoring confirms Gorlin platform availability from the geographies where hereditary skin cancer clinics, multidisciplinary Gorlin specialty programs, pediatric neuro-oncology centers, and oral maxillofacial surgery departments serve patients across their lifetime surveillance calendars.
Status Page for Gorlin Syndrome Care Team Communication
A real-time status page gives clinical geneticists confirming PTCH1/PTCH2 germline status, dermatologists performing biannual BCC surveillance examinations and managing hedgehog inhibitor therapy, oral and maxillofacial surgeons tracking KCOT recurrence after enucleation, pediatric neuro-oncologists managing radiation-free desmoplastic medulloblastoma treatment, radiation oncologists requiring Gorlin status before any radiotherapy planning, cardiologists monitoring cardiac fibromas, gynecologists performing ovarian fibroma surveillance, and genetic counselors coordinating family cascade testing immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in Gorlin syndrome molecular genetics laboratory backup procedures, annual surveillance calendar communication templates, and multidisciplinary Gorlin clinic shared coordination platforms.
Vigilmon Setup for Gorlin Syndrome Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | PTCH1/PTCH2 germline sequencing (point mutation and MLPA deletion) | 1 min | Slack + PagerDuty (lab hours) | | Radiation-avoidance alert system (EHR Gorlin flag for radiation oncology) | 1 min | Slack + PagerDuty (24/7) | | Full-body BCC surveillance (dermoscopy, photography, mapping) | 1 min | Slack + PagerDuty (clinical hours) | | BCC treatment records (excision, Mohs, PDT, imiquimod) | 1 min | Slack + PagerDuty (clinical hours) | | Hedgehog inhibitor monitoring (vismodegib/sonidegib response and toxicity) | 1 min | Slack + PagerDuty (clinical hours) | | Panoramic jaw radiograph (annual KCOT surveillance) | 1 min | Slack + PagerDuty (radiology hours) | | Post-KCOT recurrence surveillance (6–12 monthly panoramic) | 1 min | Slack + PagerDuty (radiology hours) | | Pediatric brain MRI with gadolinium (medulloblastoma surveillance 0–7 years) | 1 min | Slack + PagerDuty (radiology hours) | | Medulloblastoma treatment (radiation-free chemotherapy documentation) | 1 min | Slack + PagerDuty (clinical hours) | | Echocardiography (cardiac fibroma detection and monitoring) | 1 min | Slack + PagerDuty (clinical hours) | | Cardiac MRI (fibroma characterization and surgical planning) | 1 min | Slack + PagerDuty (clinical hours) | | Pelvic ultrasound (ovarian fibroma surveillance in females) | 1 min | Slack + PagerDuty (clinical hours) | | Brain MRI adult (meningioma surveillance) | 2 min | Slack (radiology hours) | | Skull/spine radiograph (falx calcification, rib/vertebral anomalies) | 2 min | Slack (radiology hours) | | Advanced BCC staging CT (locoregional and metastatic assessment) | 1 min | Slack + PagerDuty (radiology hours) | | Cascade family genetic testing (at-risk relatives from childhood) | 1 min | Slack + PagerDuty (lab hours) | | Genetic counseling and reproductive planning coordination | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure the radiation-avoidance alert system with 24/7 immediate alerting — this is the highest-stakes single platform in Gorlin management
- Add PTCH1/PTCH2 germline sequencing platforms with immediate laboratory-hours alerting
- Configure full-body BCC surveillance platforms with immediate clinical-hours alerting — the highest-frequency clinical obligation across the lifetime of Gorlin patients
- Add hedgehog inhibitor monitoring platforms with immediate clinical-hours alerting
- Configure panoramic jaw radiograph platforms with immediate radiology-hours alerting — KCOT surveillance begins in childhood
- Add post-KCOT recurrence surveillance platforms with immediate radiology-hours alerting
- Configure pediatric brain MRI platforms with immediate radiology-hours alerting — medulloblastoma detection before symptoms
- Add radiation-free medulloblastoma chemotherapy documentation platforms with immediate clinical-hours alerting
- Configure echocardiography platforms with immediate clinical-hours alerting
- Add cardiac MRI platforms with immediate clinical-hours alerting
- Configure pelvic ultrasound platforms with immediate clinical-hours alerting
- Add adult brain MRI platforms with sustained-failure alerting for meningioma surveillance
- Configure cascade family genetic testing platforms with immediate laboratory-hours alerting
- Add genetic counseling coordination platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all platforms — with immediate escalation protocols for radiation oncology treatment planning system certificate failures
- Add the status page URL to Gorlin syndrome surveillance calendar templates and multidisciplinary clinic coordination platforms
Conclusion
Gorlin syndrome technology platforms are embedded in clinical decisions where radiation oncology treatment planning platform availability — the single most consequential platform availability requirement in all of Gorlin syndrome care — determines whether a 4-year-old child presenting with a desmoplastic cerebellar tumor who has not yet received a formal Gorlin syndrome genetics evaluation can have their PTCH1 germline status surfaced in the treatment planning electronic health record before the radiation oncology team plans the craniospinal irradiation that, in a Gorlin patient, would over the following months trigger the formation of thousands of BCCs across every radiation-exposed skin surface, transforming a child whose medulloblastoma was potentially curable with surgery and radiation-free chemotherapy into a patient managing catastrophic post-radiation BCC formation for the remainder of their life — a clinical catastrophe made entirely preventable by prospective Gorlin diagnosis and the PTCH1 radiation-sensitivity annotation that must reliably surface in treatment planning systems before radiation orders are entered; where panoramic jaw radiograph platform availability during the annual surveillance of a 12-year-old Gorlin patient — when the oral maxillofacial surgeon is comparing the current panoramic study against the prior year's imaging to determine whether the 8 mm asymptomatic mandibular lucency at the right third molar position has expanded to a size and cortical morphology warranting enucleation before pathological fracture risk increases — cannot be disrupted by dental radiology platform failures that deny the comparison study needed to assess whether conservative surveillance can continue or surgical intervention should be scheduled; and where full-body BCC surveillance platform availability during the quarterly dermatological examination of a 32-year-old Gorlin patient with known high BCC burden — when the dermatologist is using total body photography and dermoscopy to detect whether any of the 47 mapped lesions have grown beyond dermoscopic criteria thresholds and whether any new lesions have appeared in sites requiring Mohs surgery — cannot be disrupted by photographic mapping platform failures that prevent the serial comparison needed to identify rapidly growing BCCs requiring urgent excision before locally advanced behavior develops. A radiation oncology treatment planning alert system unavailable when a Gorlin patient's craniospinal radiation order is being entered, a panoramic jaw radiograph archive unavailable when KCOT growth rate assessment determines surgical timing, a full-body BCC photographic mapping platform interrupted when serial comparison detects accelerating BCC growth — these are not IT incidents. They are clinical disruptions in the management of the most medically complex hereditary BCC predisposition syndrome in dermatological oncology, whose hedgehog pathway mechanism, radiation catastrophe risk, jaw KCOT burden, medulloblastoma management imperatives, and hedgehog inhibitor therapeutic era make BCC surveillance platform continuous availability the highest-frequency clinical obligation, jaw radiology platform reliability the foundation of KCOT detection and recurrence monitoring, and radiation oncology treatment planning platform availability the single most consequential safety system in Gorlin syndrome care.
Uptime monitoring gives Gorlin syndrome tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to hereditary skin cancer programs, multidisciplinary Gorlin specialty clinics, pediatric neuro-oncology centers, and compliance auditors that platform operational reliability matches the BCC surveillance intensity, radiation-avoidance safety requirements, KCOT management obligations, and hedgehog inhibitor therapeutic monitoring demands of modern Gorlin syndrome care.
Start monitoring your Gorlin syndrome care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #gorlin #syndrome #NBCCS #nevoid #basalcell #carcinoma #PTCH1 #PTCH2 #hedgehog #SMO #vismodegib #sonidegib #medulloblastoma #keratocyst #KCOT #ovarianfibroma #cardiacfibroma #radiation #avoidance #tumorsuppressor #hereditary #HIPAA #healthtech #digitalhealth #uptime #sre